Yuetong Zhong

Yuetong Zhong

Auto-generated profile, based on publicly available information

Yuetong Zhong

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Integrative Cancer Therapies
Verified
Journal Article
Open access
TYTiantian Yang
Tiantian Yang
CWCaixian Wu
Caixian Wu
PLPeicong Li
Peicong Li
YZYuetong Zhong
Yuetong Zhong
WWWanyin Wu
Wanyin Wu
XYXiaobing Yang
Xiaobing Yang
Objective: The purpose of this overview is to assess systematic reviews (SRs)/ meta-analyses (MAs) of Huachansu (HCS) combination chemotherapy for treating non-small cell lung cancer (NSCLC) and provide summarized evidence for clinical decision making. Methods: From the creation of the database to JUNE 2023, 8 databases in English and Chinese were searched. SRs/MAs that met the inclusion and exclusion criteria were included. Two reviewers independently screened research, extracted data and assessed methodological quality, risk of bias, report quality and evidence quality by using relevant criteria from AMSTAR-2, ROBIS scale, PRISMA, and GRADE system. Results: The short-term effect, long-term effect, quality of life improvement, safety and pain relief effect in 8 included SRs/MAs were assessed in this overview according to quantitative synthesis. Results assessed by AMSTAR-2, PRISMA, and ROBIS were generally unsatisfactory, with the results of the AMSTAR-2 assessment showing that all of them were of low or critically low quality; the number of items in the included research that were fully reported (compliance was 100%) by the PRISMA checklist was only 50%, while there were 38.10% of the research reporting less than 60% completeness; the ROBIS assessment showed a small number of systems to be low risk of bias. In addition, 26 items were rated as moderate quality, while 50.94% of items were rated as low or critically low quality by GRADE. Conclusion: HCS may be a promising adjuvant therapy for NSCLC. However, high-quality SRs/MAs and randomized control trials (RCTs) should be conducted to provide sufficient evidence so as to draw a definitive conclusion.

1 January 2025 in Integrative Cancer Therapies
Verified
Journal Article
Open access
CWCaixian Wu
Caixian Wu
PLPeicong Li
Peicong Li
HYHuiling Yang
Huiling Yang
YZYongchun Zou
Yongchun Zou
PHPengrong Hu
Pengrong Hu
XYXiaobing Yang
Xiaobing Yang
Objective: To evaluate the effectiveness and safety of Shenyi Capsule (SC) combined with conventional anticancer therapies through a comprehensive assessment of systematic reviews/meta-analyses (SRs/MAs), identify limitations in current evidence, and provide evidence-based guide for clinical practice and research. Methods: Registered in PROSPERO (CRD42024573610), this study searched 8 Databases from inception to November 10, 2024. Two separate reviewers were responsible for selecting studies, collecting data, assessing quality, and evaluating the potential for bias, with this research incorporating only SRs/MAs based on randomized controlled trials and utilizing 4 tools (AMSTAR-2, PRISMA 2020, ROBIS, GRADE) to evaluate methodological quality and risk of bias. Results: Thirteen SRs/MAs were included, focusing on 4 cancer types. AMSTAR-2 evaluations revealed no high quality studies. Compliance with PRISMA 2020 guidelines was below 50% for most items, with major deficiencies including lack of protocol registration, incomplete abstracts and search strategies, inappropriate or missing risk-of-bias assessments, insufficient descriptions of data transformation methods, absence of heterogeneity and sensitivity analyses, and failure to report funding sources. ROBIS indicated high bias risk in 11 studies. GRADE assessment of 109 outcomes showed evidence quality as moderate (40.37%), low (34.86%), or very low (24.77%). Discussion: SC may enhance efficacy and safety as an adjuvant cancer therapy. However, methodological flaws in existing SRs/MAs limit reliability. Future research should prioritize standardized SR/MA protocols and RCT designs to improve evidence quality, reduce bias, and strengthen clinical applicability.